Inhibikase Therapeutics Inc (NAS:IKT)
$ 3.05 -0.01 (-0.33%) Market Cap: 204.94 Mil Enterprise Value: 202.51 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Inhibikase Therapeutics Inc at Sachs Associates Neuroscience Innovation Forum (Virtual) Transcript

Apr 28, 2021 / 05:20PM GMT
Release Date Price: $32.58 (-2.51%)
Milton Werner
Inhibikase Therapeutics, Inc. - President & CEO

Well, good afternoon. I want to thank the organizers of the Sachs neuroscience conference for inviting Inhibikase to present some of its early clinical and mechanistic insights into Parkinson's disease. We are a publicly listed company on the NASDAQ with the symbol IKT. And what I'll be discussing today are therapies in clinical development to reverse the progression of Parkinson's disease in human patients, something that we recognize is a bold statement to make, but we'll try to illustrate why we think such therapeutic outcomes may be possible.

I just need to make a disclosure on the next slide, related to the fact that I'm making forward-looking statements. We have a number of public filings, and I encourage anyone interested to learning more about the company to review those filings in their entirety.

As an overview, Parkinson's disease is a very large market. We expect the Parkinson's disease market to double over the next few years. It is already a $6 billion-plus sales market. And the country with the largest

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot